Login to Your Account



Asking For More Data, FDA Places Hold On DOV's Ocinaplon Phase III

By Kim Coghill


Monday, October 6, 2003
The FDA placed a hold on DOV Pharmaceutical Inc.'s pivotal Phase III trial for an anti-anxiety candidate, asking for additional safety data. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription